TNFRSF8 and lymphoma: CD30 is widely expressed in various types of lymphomas, and clinical studies in the last decade have demonstrated that this molecule is a high-value therapeutic target for lymphomas, and utilization of this target can improve the prognosis of patients with different CD30+lymphomas.